- Home
- FLYE vs AIMD Comparison
FLYE vs AIMD Comparison
Compare FLYE & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- AIMD
- Stock Information
- Founded
- FLYE 2018
- AIMD 1984
- Country
- FLYE United States
- AIMD United States
- Employees
- FLYE N/A
- AIMD N/A
- Industry
- FLYE Aerospace
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- AIMD Health Care
- Exchange
- FLYE Nasdaq
- AIMD Nasdaq
- Market Cap
- FLYE 10.2M
- AIMD 8.2M
- IPO Year
- FLYE 2024
- AIMD N/A
- Fundamental
- Price
- FLYE $0.52
- AIMD $0.54
- Analyst Decision
- FLYE
- AIMD
- Analyst Count
- FLYE 0
- AIMD 0
- Target Price
- FLYE N/A
- AIMD N/A
- AVG Volume (30 Days)
- FLYE 117.4K
- AIMD 168.9K
- Earning Date
- FLYE 05-23-2025
- AIMD 05-12-2025
- Dividend Yield
- FLYE N/A
- AIMD N/A
- EPS Growth
- FLYE N/A
- AIMD N/A
- EPS
- FLYE N/A
- AIMD N/A
- Revenue
- FLYE $28,547,111.00
- AIMD $20,729.00
- Revenue This Year
- FLYE N/A
- AIMD N/A
- Revenue Next Year
- FLYE N/A
- AIMD N/A
- P/E Ratio
- FLYE N/A
- AIMD N/A
- Revenue Growth
- FLYE N/A
- AIMD N/A
- 52 Week Low
- FLYE $0.33
- AIMD $0.40
- 52 Week High
- FLYE $7.62
- AIMD $1.46
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- AIMD 50.95
- Support Level
- FLYE N/A
- AIMD $0.51
- Resistance Level
- FLYE N/A
- AIMD $0.57
- Average True Range (ATR)
- FLYE 0.00
- AIMD 0.04
- MACD
- FLYE 0.00
- AIMD -0.00
- Stochastic Oscillator
- FLYE 0.00
- AIMD 36.71
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.